Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study Read more about Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery Read more about Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment Read more about Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Read more about Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Read more about Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The Impact of Sexual Health and Amputation Focused Education on Regulation of Glucose and Amputation Prevention Read more about The Impact of Sexual Health and Amputation Focused Education on Regulation of Glucose and Amputation Prevention
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Read more about Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer Read more about Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Read more about Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients